The reaffirmed full-year guidance and strong Sterigenics/Nelson Labs growth suggest operational momentum is intact. Watch for any updates on EO litigation developments and Nordion's Co-60 harvest schedule recovery in Q4.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 3 $16.03entry
- T+1 · 2d ago +2.25%α +0.59% · $16.39
- T+3 · todayOpen
- T+5 · in 4d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Sotera Health reported Q3 2026 adjusted EPS of $0.29, beating the $0.27 consensus by 7.4%, and revenue of $324.9M, above the $319.9M estimate. The company reaffirmed its full-year constant currency revenue growth outlook of 5.25%-6.75% and adjusted EBITDA growth of 5.75%-7.25%. Sterigenics and Nelson Labs posted strong constant currency revenue growth of 8.2% and 9.2%, respectively, while Nordion declined 11.5% due to Co-60 harvest timing.
Key Financial Metrics
Key Facts
- Q3 2026 adjusted EPS of $0.29, up 12% YoY, above consensus of $0.27
- Q3 2026 total net revenues of $324.9M, up 4.4% YoY, above consensus of $319.9M
- Sterigenics revenue grew 8.2% constant currency to $209M; Nelson Labs grew 9.2% to $61M
- Nordion revenue declined 11.5% constant currency to $55M due to Co-60 harvest timing
- Adjusted EBITDA margin improved sequentially ~100 bps to 52.5%
- Net leverage ratio improved to 2.9x from 3.2x at year-end 2025
- Full-year 2026 outlook reaffirmed: revenue $1.233B-$1.250B, adjusted EBITDA $632M-$641M
- Credit rating upgraded by Moody's in early October 2026
- Operating cash flow of $111M in Q3 2026
Financial Impact
EPS beat of $0.02 (7.4%) on $324.9M revenue vs $319.9M consensus; revenue growth of 4.4% YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Sterigenics | $209.3M | +8.5% |
| Nordion | $55.0M | -12.4% |
| Nelson Labs | $60.6M | +8.8% |
Risk Factors
- Ongoing EO litigation exposure and associated professional fees ($11.7M in Q3)
- Nordion revenue volatility tied to Co-60 harvest timing
- Foreign exchange headwinds (revenue guidance revised to 70 bps benefit from 100 bps)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394046 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 3d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Nov 3, 2026 3d ago | Press Release | $16.03 $16.39 | ▲ +2.25% | ▲ +0.59% | $15.94 (−0.56%) |
Oct 30, 2026 7d ago | SC 13G | $18.15 $17.74 | ▼ −2.26% | ▼ −1.78% | $15.94 (−12.18%) |
Oct 21, 2026 15d ago | Institutional Cluster | $18.13 $18.10 | ▼ −0.17% | ▲ +0.36% | $15.94 (−12.08%) |
Oct 9, 2026 27d ago | SC 13G/A | $18.15 $18.21 | ▼ −0.33% | ▼ −0.34% | $15.94 (+12.18%) |
Aug 14, 2026 12w ago | 8-K | $18.89 $18.80 | ▼ −0.48% | ▼ −0.00% | $15.94 (−15.62%) |
Aug 9, 2026 12w ago | Institutional Cluster | $18.97 $19.11 | ▲ +0.74% | ▲ +1.06% | $15.94 (−15.97%) |
Aug 7, 2026 13w ago | 144 | $18.86 $18.97 | ▲ +0.58% | ▲ +0.61% | $15.94 (−15.48%) |
Aug 6, 2026 13w ago | 8-K | $18.91 $18.86 | ▼ −0.26% | ▼ −0.88% | $15.94 (−15.71%) |
May 27, 2026 23w ago | 3 | $15.75 $15.64 | ▼ −0.70% | ▼ −0.94% | $15.94 (+1.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers